Stifel Nicolaus cut shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) from a buy rating to a hold rating in a research report report published on Thursday, MarketBeat.com reports. Stifel Nicolaus currently has $15.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $26.00.

A number of other equities research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Acorda Therapeutics from a hold rating to a strong sell rating in a research note on Wednesday, July 19th. BidaskClub cut shares of Acorda Therapeutics from a buy rating to a hold rating in a research note on Wednesday, July 19th. Cantor Fitzgerald restated a hold rating and set a $18.00 price objective on shares of Acorda Therapeutics in a research note on Tuesday, August 29th. Cowen and Company restated a buy rating and set a $35.00 price objective on shares of Acorda Therapeutics in a research note on Tuesday, August 29th. Finally, Janney Montgomery Scott restated a hold rating and set a $18.00 price objective on shares of Acorda Therapeutics in a research note on Wednesday, August 30th. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Acorda Therapeutics currently has a consensus rating of Hold and an average price target of $21.43.

Shares of Acorda Therapeutics (NASDAQ:ACOR) opened at $18.50 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40. Acorda Therapeutics has a one year low of $13.60 and a one year high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.26). The company had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. Acorda Therapeutics had a negative net margin of 10.25% and a negative return on equity of 8.18%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.04) earnings per share. analysts predict that Acorda Therapeutics will post -0.43 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/20/acorda-therapeutics-inc-acor-downgraded-to-hold-at-stifel-nicolaus.html.

In related news, major shareholder Scopia Capital Management Lp purchased 766,201 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The shares were purchased at an average price of $19.23 per share, with a total value of $14,734,045.23. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 7.90% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Louisiana State Employees Retirement System grew its stake in Acorda Therapeutics by 0.5% during the 2nd quarter. Louisiana State Employees Retirement System now owns 19,000 shares of the biopharmaceutical company’s stock valued at $374,000 after acquiring an additional 100 shares in the last quarter. Arizona State Retirement System grew its stake in Acorda Therapeutics by 0.4% during the 2nd quarter. Arizona State Retirement System now owns 24,305 shares of the biopharmaceutical company’s stock valued at $479,000 after acquiring an additional 100 shares in the last quarter. Aperio Group LLC grew its stake in Acorda Therapeutics by 2.7% during the 2nd quarter. Aperio Group LLC now owns 12,972 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 343 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its stake in Acorda Therapeutics by 3.9% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 10,960 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 410 shares in the last quarter. Finally, Texas Permanent School Fund grew its stake in Acorda Therapeutics by 1.4% during the 2nd quarter. Texas Permanent School Fund now owns 34,066 shares of the biopharmaceutical company’s stock valued at $671,000 after acquiring an additional 466 shares in the last quarter.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Stock Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related stocks with our FREE daily email newsletter.